Compare PDLB & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | EOLS |
|---|---|---|
| Founded | 1960 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 377.3M | 444.0M |
| IPO Year | 2017 | 2018 |
| Metric | PDLB | EOLS |
|---|---|---|
| Price | $15.71 | $6.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.80 |
| AVG Volume (30 Days) | 72.7K | ★ 1.4M |
| Earning Date | 01-27-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.83 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | $96,252,000.00 | ★ $285,823,000.00 |
| Revenue This Year | $10.97 | $14.36 |
| Revenue Next Year | $8.59 | $23.27 |
| P/E Ratio | $17.65 | ★ N/A |
| Revenue Growth | ★ 26.04 | 15.10 |
| 52 Week Low | $10.88 | $5.71 |
| 52 Week High | $16.09 | $17.12 |
| Indicator | PDLB | EOLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.84 | 50.64 |
| Support Level | $15.29 | $6.36 |
| Resistance Level | $16.09 | $7.15 |
| Average True Range (ATR) | 0.42 | 0.29 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 71.65 | 55.74 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.